Salute e Benessere

Bavarian Nordic Receives Order from HERA and Announces Significant Donation of…

HERA will procure 175,420 doses for immediate response to the concerning mpox outbreak in Africa, and furthermore, Bavarian Nordic will donate 40,000 doses to HERA, also to be distributed to the Africa CDC.COPENHAGEN, Denmark, August 13, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today a new order from HERA (the European Health Emergency Preparedness and Response Authority) for the Company's MVA-BN ®vaccine, the only FDA and EMA-approved mpox vaccine. HERA will procure 175,420...
Nasdaq GlobeNewswire
13/08/2024

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; August 13, 2024 –Genmab A/S(Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to...
Nasdaq GlobeNewswire
13/08/2024

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; August 13, 2024 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 28,193 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:107 shares at DKK 962.00, 27,188 shares at DKK 1,032.00, 279 shares at DKK 1,050.00, 125 shares at...
Nasdaq GlobeNewswire
13/08/2024

Bavarian Nordic Announces FDA Acceptance and Priority Review of the BLA for its…

PDUFA target action date of February 14, 2025COPENHAGEN, Denmark, August 13, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Biologics License Application (BLA) for CHIKV VLP, the Company's vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older.The Priority Review designation means the FDA is targeting...
Nasdaq GlobeNewswire
13/08/2024

Medical Smart Textile Market Size to Grow USD 3273.6 Million by 2030 at a CAGR…

Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-3Z9383/Global_Medical_Smart_Textile_Market Get Free Sample @ https://reports.valuates.com/request/sample/QYRE-Auto-3Z9383/Global_Medical_Smart_Textile_Market Major Factors Driving the Growth of Medical Smart Textile Market: Because more sophisticated textile technologies are being incorporated into healthcare applications, the market for medical smart textiles is expanding significantly. In order to monitor,...
PR Newswire
13/08/2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024

AggregatedpresentationbydayandbymarketPurchases of own shares from August 5th to August 7th, 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1105/08/2024FR00102591509 021103,0295XPARIPSEN549300M6SGDPB4Z94P11...
Nasdaq GlobeNewswire
13/08/2024

Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic…

PRIVILEGED INFORMATIONComposition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration.Enriched IP portfolio protects arsenic trioxide (ATO) use combined with copper ions delivery, which has demonstrated increased therapeutic potential for indications ranging from immune to cancer and infectious diseases. Mont-Saint-Guibert, Belgium, 13 août 2024, 6.00pm CET –BioSenic(Euronext Brussels and Paris: BIOS), the...
Nasdaq GlobeNewswire
13/08/2024

Ramsay Sante : Ramsay Santé has successfully refinanced its Senior Debt Facility

PRESS RELEASE Paris, 13 August 2024 Ramsay Santé has successfully refinanced its Senior Debt FacilityOn 13 August 2024, Ramsay Santé completed the Amend & Extend process of its €1,650m Senior Debt facility, including a €100m revolving credit facility, a €100m capex facility, and a €1,450m Term Loan B facility, proactively extending its upcoming 2026-2027 debt maturities to 2029-2031. This transaction was arranged by BNP Paribas and Crédit Agricole CIB as Global Coordinators for...
Nasdaq GlobeNewswire
13/08/2024

Intracardiac Echocardiography (ICE) Market worth $545 million by 2029 driven by…

Browse in-depth TOC on "Intracardiac Echocardiography (ICE) Market" Browse in-depth TOC on "Intracardiac Echocardiography (ICE) Market" 261 - Tables56 - Figures 297 - Pages Abbott Laboratories: Leading Provider of Intracardiac Echocardiography Technologies Abbott Laboratories (US) is a key player in intracardiac echocardiography (ICE), offering advanced solutions such as the ViewFlex Xtra ICE Catheter and the ViewMate Ultrasound Console. These technologies provide...
PR Newswire
13/08/2024

inThought Launches the Insights Framework

inThought creates a unique roadmap for each client that identifies key business objectives across multidisciplinary teams. inThought defines when, where, and how strategic insights will be obtained to address and advance those objectives. This is executed with frequent communication and transparent timelines that allow clients to focus on their own priorities knowing that inThought has them covered. With flexibility and customization to fit any client's needs, the inThought Insights Framework is…
PR Newswire
13/08/2024

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and…

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- - Received Fast Track Designation (FTD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of metastatic pancreatic adenocarcinoma- - Received Rare Pediatric Disease Designation (RPDD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for...
Nasdaq GlobeNewswire
13/08/2024

Notice of Nexstim Plc's Half-Year Report H1 2024

Press release,Helsinki,13 August2024 at 3 PM(EEST) Noticeof NexstimPlc's Half-Year Report H1 2024 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") will publish its half-yearly report for the six months ended 30 June 2024 on Friday 16 August 2024 at approximately 9:00 am Finnish time.The company will hold two live webinars for media, investors, and analysts on Friday 16 August 2024. CEO Mikko Karvinen and CFO Joonas Juokslahti will present the financial and operational...
Nasdaq GlobeNewswire
13/08/2024

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for…

Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive...
Nasdaq GlobeNewswire
13/08/2024

BioSenic S.A. : Transparency notification received from ABO Infinium Americas…

REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, August 13, 2024, 1.00pm CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of...
Nasdaq GlobeNewswire
13/08/2024

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months; IMA203 continues to maintain a favorable tolerability profileRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 in 2L+ melanoma planned to commence in 2024 Next data update on IMA203 and IMA203CD8 (GEN2) to be presented at medical conferences in 2H 2024First...
Nasdaq GlobeNewswire
13/08/2024

Anti Aging Products Market to Reach $108.5 Billion, Globally, by 2033 at 6.9%…

Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06331 Download Sample Pages of Research Overview: https://www.alliedmarketresearch.com/request-sample/A06331 Prime determinants of growth The prime determinants of growth in the anti-aging products market include technological advancements, increasing consumer awareness, and evolving beauty trends. Innovations in skincare technology, such as the development of more effective active...
PR Newswire
13/08/2024

MolecuLight's Breakthrough Imaging Technology Promotes Health Equity in Wound…

Disproportionally poor health outcomes are near-universal for Black Americans, including wounds. Between 2013-2014, Black Americans with diabetic ulcers in rural areas faced double the risk of major leg amputation or death following hospitalization compared to their White counterparts residing in similar regionsii. "There are now technologies that can identify more Black patients with wound infections who can be treated more efficaciously to prevent infection complications including…
PR Newswire
13/08/2024

Image-Guided Radiation Therapy Market to Reach $3.3 Billion, Globally, by 2033…

Request Sample of the Report on Image-Guided Radiation Therapy Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A323701 Request Sample of the Report on Image-Guided Radiation Therapy Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A323701 Prime determinants of growth Image-guided radiation therapy (IGRT) is experiencing significant growth due to several key drivers such as technological advancements in imaging modalities such as...
PR Newswire
13/08/2024

Intravenous (IV) Hydration Therapy Market to Reach $4.9 Billion, Globally, by…

Request Sample of the Report on Intravenous (IV) Hydration Therapy Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A323708 Request Sample of the Report on Intravenous (IV) Hydration Therapy Market Forecast 2033 -https://www.alliedmarketresearch.com/request-sample/A323708 Prime determinants of growth Increasing prevalence of dehydration-related conditions, and growing health and wellness trends are the major factors that drive the growth of the...
PR Newswire
13/08/2024

Salt Medical: A New Medical Device Design Contract Manufacturer to open in…

Who is Salt Medical? Salt Medical establishes a renowned international medical device platform with an extensive global research and development (R&D) and manufacturing infrastructure. The company operates R&D and manufacturing facilities inIreland, along with raw material and precision component supply and large-scale manufacturing facilities in theUnited Statesand theAsia Pacificregion. Specialising in the production of catheters, guidewires, medical...
PR Newswire
13/08/2024

Philips and Dutch Isala Hospital renew long-term partnership focused on…

Amsterdam, The Netherlands– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Isala hospital (Zwolle, The Netherlands) have renewed their long-term strategic partnership to enhance healthcare delivery through innovative and cost-effective solutions. This collaboration aims to ensure healthcare remains accessible, available, and affordable by leveraging Philips' advanced technology, data analytics, and AI. Focusing on the radiology and cardiology...
Nasdaq GlobeNewswire
13/08/2024

Regenics AS completes first tranche of a NOK 54 M private placement to initiate…

Each Unit consists of one common share in Regenics AS and one- and one-half share purchase warrants (a "Warrant"). Each Warrant will entitle Nordic Blue to purchase one common share, at a price of NOK 9 per unit, until December 31st 2024, representing an additional capital raise of 34 MNOK. Each Unit consists of one common share in Regenics AS and one- and one-half share purchase warrants (a "Warrant"). Each Warrant will entitle Nordic Blue to purchase one common share, at a…
PR Newswire
13/08/2024

Calliditas Interim Report January to June 2024

January to June 2024 (compared to January to June 2023) January toJune 2024(compared to January toJune 2023 ) Key takeaways from Q2, 2024 Key events after the reporting period Asahi Kasei Offer Outlook 2024: Updated Calliditas expects continued revenue growth: Total net sales from the Nefecon franchise, including milestones, are estimated to beUSD 165 -185 million for the year endingDecember 31, 2024. Investor Presentation Today, 13 August at2...
PR Newswire
13/08/2024

Basilea reports strong 2024 half-year results and significantly increases…

Continued success of Cresemba ®with 16.6% growth of royalties to CHF 42.8 million Operating result of CHF 9.3 million, net profit of CHF 20.7 millionTotal revenue guidance increased by 7% to CHF ~196 million and operating profit guidance increased by 20% to CHF ~36 million Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, August 13, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
Nasdaq GlobeNewswire
13/08/2024
Altri  Comunicati